Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

XINGLONG ZHENG

Allopathic & Osteopathic Physicians Pathology Blood Banking & Transfusion Medicine

NPI
1205988599
CMS profile
1367778
Location
BIRMINGHAM, AL

General Payments · PY2018–2024

$176,273.08

  • Reported across 183 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$21,147.57

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
GENZYME CORPORATION $14,277.74 8
Takeda Pharmaceuticals U.S.A., Inc. $6,869.83 5

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $33,840.37 60
PY2019 $41,264.60 58
PY2020 $36,744.99 24
PY2021 $19,190.37 13
PY2022 $17,438.73 7
PY2023 $6,646.45 8
PY2024 $21,147.57 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
GENZYME CORPORATION $3,774.75 06/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1139875300 CMS
GENZYME CORPORATION $9,061.00 11/18/2024 Consulting Fee Undisputed 01/23/2026 1139875302 CMS
GENZYME CORPORATION $190.76 11/18/2024 Food and Beverage Undisputed 01/23/2026 1139875304 CMS
GENZYME CORPORATION $465.00 11/18/2024 Travel and Lodging Undisputed 01/23/2026 1139875306 CMS
GENZYME CORPORATION $360.47 11/18/2024 Travel and Lodging Undisputed 01/23/2026 1139875308 CMS
GENZYME CORPORATION $339.63 11/18/2024 Travel and Lodging Undisputed 01/23/2026 1139875310 CMS
GENZYME CORPORATION $14.74 11/18/2024 Travel and Lodging Undisputed 01/23/2026 1139875312 CMS
GENZYME CORPORATION $71.39 11/18/2024 Food and Beverage Undisputed 01/23/2026 1139875470 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,605.00 04/29/2024 Consulting Fee Undisputed 01/23/2026 1137702922 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.88 06/23/2024 Food and Beverage Undisputed 01/23/2026 1137702924 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.45 06/23/2024 Travel and Lodging Undisputed 01/23/2026 1137702926 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,872.50 08/06/2024 Consulting Fee Undisputed 01/23/2026 1137702928 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,375.00 08/14/2024 Consulting Fee Undisputed 01/23/2026 1137702930 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.